Testing a new brain scan tracer for Huntington's disease
Part of Brain & nervous system, Genetic & congenital, Mental health clinical trials.
This trial tests a new radioactive tracer called [11C]CHDI-00491009 that may show mutant huntingtin protein in the brain using a PET scan. It aims to find out if the tracer is safe and helps see Huntington's disease changes. If you have early-stage Huntington's or are a healthy volunteer, you may be able to join.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 64 years old.
- Your weight and height give a body mass index (BMI) between 19 and 35.
- You are willing to travel to Leuven, Belgium for the imaging visit.
- You can give written consent and follow study procedures like fasting and blood draws.
- If you have Huntington's, your CAG repeat count must be between 40 and 50 and your disease stage must be 2 or 3.
- If you are a healthy volunteer, you must have no family history of Huntington's, or if you do, you must have tested negative for the gene.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study compares two different brain imaging tracers to see which one shows Huntington disease brain changes better. It may help improve how doctors measure and track Huntington disease using PET-MRI scans.
This study uses repeat brain scans (including PET and MRI) to track changes in the brain caused by Huntington’s disease over time. It may help researchers understand disease progress and test how well the scans reflect early vs later disease.
This study uses special brain imaging and memory/thinking tests to find early “markers” that can predict how Huntington’s disease will progress over time. You may qualify as someone with early-stage Huntington’s or as a healthy control, if you meet specific safety and scoring requirements.
This study tests how a healthy male body absorbs, uses, and removes a new experimental medication. Researchers track the drug's path through your body using a special radioactive marker to understand how it works and ensure it's safe.
This trial tests a new drug called SKY-0515 in people with Huntington's disease. The goal is to see if it can safely improve symptoms or slow the disease down.
This trial tests a gene therapy called SPK-10001 for people with early-stage Huntington's disease. It aims to slow the progression of symptoms by targeting the genetic cause of the disease.
Hear when a new Huntington Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.